Synmosa Biopharma Corporation (TPEX:4114)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
27.85
0.00 (0.00%)
Nov 10, 2026, 1:30 PM CST

Synmosa Biopharma Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6,6796,1895,5505,1404,3863,235
Revenue Growth
11.40%11.53%7.96%17.19%35.59%6.47%
Gross Profit
2,7502,6792,4012,1201,8271,285
Operating Income
714.96778.52740.97616.81460.71186.74
Net Income
827.17821.85684.68594.83799.09303.86
Earnings Per Share
1.531.541.371.231.710.64
EPS Growth
8.55%12.16%11.49%-28.30%166.12%-53.74%

Revenue by Segment

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Intersegment Income
-275.82-276.9-210.22-146.19-86.89-31.13
Pharmaceutical Ingredients Department
413.7467.25363.24325.78234.87119.57
New Drugs Segment
6,5415,9995,3974,9614,2383,147
Total
6,6796,1895,5505,1404,3863,235

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
2,7802,9311,8821,6501,418988.43
Total Debt
3,3322,5132,5492,4333,3553,463
Net Cash (Debt)
-551.87418.19-666.47-782.59-1,937-2,474
Net Cash Growth
------
Net Cash Per Share
-1.020.78-1.33-1.62-4.16-5.27

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
384.05411.57780.62511.93630.25454.86
Capital Expenditures
-186.41-255.44-214.52-207.04-129.3-93.06
Free Cash Flow
197.64156.14566.1304.89500.95361.81
Free Cash Flow Growth
-58.87%-72.42%85.68%-39.14%38.46%261.83%

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
41.17%43.28%43.26%41.24%41.64%39.73%
Operating Margin
10.70%12.58%13.35%12.00%10.50%5.77%
Pretax Margin
11.65%12.92%11.88%11.70%16.53%4.76%
Profit Margin
12.38%13.28%12.34%11.57%18.22%9.39%
FCF Margin
2.96%2.52%10.20%5.93%11.42%11.18%

Dividends

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Dividend Per Share
0.7870.7870.5560.4590.4200.322
Dividend Per Share Growth
52.92%41.67%20.97%9.28%30.37%89.42%
Dividend Yield
2.83%2.63%1.91%1.56%1.22%2.15%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
18.2319.7721.1824.7220.0523.09
Forward PE
-15.3615.6318.0821.7951.28
P/FCF Ratio
76.25104.0625.6148.2431.9819.39
PS Ratio
2.262.632.612.863.652.17